(Q51480621)

5 April 2018

title

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. (English)

1 reference

5 April 2018

1 reference

1 reference

1 reference

1

1 reference

5 April 2018

Angela D'Angelo

2

1 reference

5 April 2018

Arrigo F. Cicero

12

1 reference

5 April 2018

author name string

Ragonesi PD

3

1 reference

5 April 2018

Ciccarelli L

4

1 reference

5 April 2018

Piccinni MN

5

1 reference

5 April 2018

Pricolo F

6

1 reference

5 April 2018

Salvadeo SA

7

1 reference

5 April 2018

Montagna L

8

1 reference

5 April 2018

Gravina A

9

1 reference

5 April 2018

Ferrari I

10

1 reference

5 April 2018

Paniga S

11

1 reference

5 April 2018

publication date

1 February 2007

1 reference

5 April 2018

Internal Medicine Journal

published in

1 reference

5 April 2018

volume

37

1 reference

5 April 2018

issue

2

1 reference

5 April 2018

page(s)

79-86

1 reference

5 April 2018

Rationale and options for combination therapy in the treatment of Type 2 diabetes

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Combining sulfonylureas and other oral agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Thiazolidinediones -- some recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Adherence to a fixed-dose combination of rosiglitazone maleate/metformin hydrochloride in subjects with type 2 diabetes mellitus: a retrospective database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Thiazolidinediones and blood lipids in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1445-5994.2007.01238.X

10.1111/J.1445-5994.2007.01238.X

21 January 2018

Identifiers

DOI

1 reference

5 April 2018

PubMed ID

17229249

1 reference

5 April 2018